Patent ID: 8492344
Filing Date: 2013-07-23
Classification: A61K,A61P,C07K,C12N

Abstract:
1. A method of treating a subject suffering from or susceptible to a cell proliferation related disorder or disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a pyruvate dehydrogenase kinase 2 (PDK2) enzyme inhibitor that is selected from the group consisting of 2-methylbut-2-enedioic acid (Compound 10), 2-(3H-imidazol-4-yl)acetic acid (Compound 14), 2-(carbamoylamino)-2-methoxyacetic acid (Compound 17), (E)-3-chlorobut-2-enoic acid (Compound 18), thiadizaole-4-carboxylic acid (Compound 19), 4-amino-6-oxo-3H-pyrimidine-2-carboxylic acid (Compound 20), (Z)-3-bromoprop-2-enoic acid (Compound 21), (Z)-but-2-enoic acid (Compound 24), and salts thereof, to thereby treat the subject suffering from or susceptible to a cell proliferation related disorder or disease.